July 21, 2025 a 09:00 pm
BMY: Analysts Ratings - Bristol-Myers Squibb Company
The current sentiment around Bristol-Myers Squibb Company (BMY) appears relatively stable with a predominant number of analysts recommending a Hold position. The company continues to show resilience in its diverse biopharmaceutical offerings despite some challenges in broader market conditions. Analyst ratings over recent months suggest a cautious approach towards investment, reflecting both opportunities in the biopharmaceutical sector and uncertainties in broader economic conditions.
Historical Stock Grades
| Recommendation | Number of Analysts | Score Bar |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 3 | |
| Hold | 18 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, analyst sentiment for Bristol-Myers Squibb has depicted a clear trend of consolidation with minor shifts. Key observations include: - The number of Hold recommendations has remained consistent and dominant, indicating market caution. - Despite moments of fluctuation, the Strong Buy and Buy categories have seen minimal change. - Overall, the total number of analyst ratings has stabilized, underlining a consistent sentiment.
Percentage Trends
Analysis over the past year demonstrates notable shifts in analyst recommendations: - Strong Buy ratings have decreased, reflecting possible short-term uncertainty or risk aversion. - Hold ratings have become more predominant, indicating a cautious or neutral stance by analysts. - There was a shift from Buy to Hold commands, suggesting heightened scrutiny over growth projections. - The most pronounced changes are observed in reduced Buy recommendations. This signals increased prudence among analysts.
Latest Analyst Recommendations
Analyst recommendations for Bristol-Myers Squibb over recent quarters primarily exhibited stability. Highlighted recommendations include:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-07-10 | Underweight | Underweight | Morgan Stanley |
| 2025-04-28 | Equal Weight | Equal Weight | Wells Fargo |
| 2025-04-23 | Neutral | Neutral | Cantor Fitzgerald |
| 2025-04-23 | Buy | Buy | Jefferies |
| 2025-04-11 | Neutral | Neutral | UBS |
Analyst Recommendations with Change of Opinion
Instances where analysts have modified their stance indicate a responsive approach to altering market dynamics. Noteworthy changes include:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-12-16 | Buy | Hold | Jefferies |
| 2024-11-12 | Outperform | Market Perform | Leerink Partners |
| 2024-10-25 | Neutral | Buy | Citigroup |
| 2024-07-29 | Underweight | Equal Weight | Barclays |
Interpretation
Based on the data, Bristol-Myers Squibb holds steady interest among analysts as a stable biopharmaceutical entity. Despite some downgrades, the prevailing Hold ratings underscore a neutral outlook. Analysts' restrained optimism may suggest a balanced view of the company's potential against industry risks. The stability in ratings suggests confidence yet caution given the uncertain global biopharmaceutical landscape. It remains crucial for investors to keep abreast of both company-specific and broader market developments.
Conclusion
The analysis of Bristol-Myers Squibb’s analyst ratings provides insights into market sentiment, characterized by a prevailing cautious optimism. With a predominantly Hold stance, analysts reflect a neutral perspective matching current market trends of volatility and uncertainty in biopharmaceuticals. Opportunities lie in potential product developments, while risks are intertwined with market competitiveness and regulatory scrutiny. The evolving sentiment showcases a stable yet watchful approach, highlighting the need for ongoing analysis for strategic investment decisions.